Clinical Trial Update: Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 bioequivalence study comparing Tiotropium 18 μg inhalation powder in a hard capsule to Spiriva Handihaler 18 μg in COPD patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva Handihaler 18 μg inhalation powder, hard capsule (tiotropium)
• Tiotropium 18 μg inhalation powder, hard capsule (tiotropium)

Snippet

Sponsor: Xiromed LLC | Conditions: COPD | Phase 3 | Status: COMPLETED